{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:58Z","timestamp":1793502718159,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2021.10.020","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T01:28:15Z","timestamp":1636853295000},"page":"430-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-6123","authenticated-orcid":false,"given":"Athena L.V.","family":"Hobbs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1278-9662","authenticated-orcid":false,"given":"Kerry O.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-4241","authenticated-orcid":false,"given":"Kimberly","family":"Saddler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Sierra-Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.10.020_bib0001","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs. ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jgar.2021.10.020_bib0002","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.020_bib0003","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2021.10.020_bib0004","first-page":"591802","article-title":"Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City","author":"Abdallah","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.020_bib0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.10.020_bib0006","series-title":"Eravacycline [package insert]","year":"2018"},{"issue":"1","key":"10.1016\/j.jgar.2021.10.020_bib0007","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1093\/ofid\/ofy210.1634","article-title":"Efficacy of eravacycline in secondary bacteremia: a post hoc analysis of two phase 3 studies in complicated intra-abdominal infection","volume":"5","author":"Lawrence","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.jgar.2021.10.020_bib0008","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase 1, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.020_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00275-18","article-title":"Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits","volume":"62","author":"Petraitis","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.020_bib0010","unstructured":"US Centers for Disease Control and Prevention (CDC). Healthcare-associated infections (HAIs): CRE definition. https:\/\/www.cdc.gov\/hai\/organisms\/cre\/definition.html [accessed December 2020]."},{"key":"10.1016\/j.jgar.2021.10.020_bib0011","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"10.1016\/j.jgar.2021.10.020_bib0012","series-title":"Linezolid [package insert]","year":"2008"},{"key":"10.1016\/j.jgar.2021.10.020_bib0013","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1089\/sur.2020.241","article-title":"Efficacy and tolerability of eravacycline in bacteremic patients with complicated intra-abdominal infection: a pooled analysis from the IGNITE1 and IGNITE4 studies","volume":"22","author":"Grant-Di Felice","year":"2021","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.jgar.2021.10.020_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.020_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin plus piperacillin\u2013tazobactam and acute kidney injury in adults: a systematic review and meta-analysis","volume":"46","author":"Luther","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2021.10.020_bib0016","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/phar.2607","article-title":"Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: how viable are the current options?","volume":"41","author":"O'Donnell","year":"2021","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.jgar.2021.10.020_bib0017","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.020_bib0018","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkaa289","article-title":"In vitro activity of eravacycline against common ribotypes of Clostridioides difficile","volume":"75","author":"Basseres","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:54Z","timestamp":1761991194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":18,"alternative-id":["S2213716521002472"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.020","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}